GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives - PubMed
3 days ago
- #Metabolic Health
- #Obstructive Sleep Apnea
- #Tirzepatide
- Obstructive sleep apnea syndrome (OSAS) is linked to obesity and metabolic dysfunction.
- Tirzepatide, a GLP-1/GIP dual agonist, shows superior weight loss and metabolic benefits compared to single GLP-1 agonists.
- Tirzepatide may reduce OSAS by affecting adiposity, inflammation, and neuromuscular regulation.
- Early studies indicate promising decreases in body weight, apnea-hypopnea index (AHI), and inflammation, but long-term trials are needed.
- Integrating tirzepatide with existing OSAS therapies could enhance pharmacologic management of obesity-related OSAS.